FUNDAMENTALS |
MarketCap: |
11 197 mill
|
EPS: |
19.82
|
P/E: |
12.00
|
Earnings Date: |
May 01, 2024 |
SharesOutstanding: |
47.06 mill
|
Avg Daily Volume: |
0.451 mill
|
RATING
2024-04-19 |
A+
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Buy
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Buy
|
|
P/E: |
Buy
|
|
Price To Book: |
Neutral
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | n/a | n/a | n/a | n/a | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE 12.00 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
2.04x
|
Company: PE 12.00 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
$362.74
(52.46%)
$124.81
|
Date: 2024-04-19
|
Expected Trading Range (DAY) |
$ 230.29 - 245.57
( +/- 3.21%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-04-17 | Rothblatt Martine A | Sell | 3 600 | Stock Options |
2024-04-18 | Rothblatt Martine A | Sell | 3 600 | Stock Options |
2024-04-18 | Rothblatt Martine A | Buy | 3 600 | Common Stock |
2024-04-18 | Rothblatt Martine A | Sell | 125 | Common Stock |
2024-04-17 | Rothblatt Martine A | Sell | 134 | Common Stock |
INSIDER POWER |
-43.59
|
Last
100 transactions |
Buy:
102 660 | Sell:
261 341 |
Forecast:
16:00 - $238.08
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $238.08
Forecast 2: 16:00 - $238.08
Forecast 3: 16:00 - $238.08
SCORE
9.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$237.93 (0.42% )
|
Volume |
0.362 mill
|
Avg. Vol. |
0.451 mill
|
% of Avg. Vol |
80.24 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For UTHR
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:36 | sell | $211.26 | N/A | Active |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.